Alpha-1 Antitrypsin Level of 216 mg/dL in a Female with Persistent Shortness of Breath
An alpha-1 antitrypsin (AAT) level of 216 mg/dL is normal and effectively rules out AAT deficiency as the cause of this patient's shortness of breath. You should pursue alternative diagnoses for her respiratory symptoms.
Interpretation of the AAT Level
The reported value of 216 mg/dL falls well within the normal reference range for AAT:
- Normal AAT range: 90-200 mg/dL by standard nephelometry 1, or 120-200 mg/dL in some references 1
- Severe deficiency threshold: <57 mg/dL (<11 μmol/L) 2, 3
- Intermediate/borderline range: 90-140 mg/dL 4
- Protective threshold: >80 mg/dL (approximately 11 μmol/L) 5
At 216 mg/dL, this patient has AAT levels that are actually slightly above the typical upper limit of normal, providing more than adequate antiprotease protection against neutrophil elastase-mediated lung damage.
Clinical Significance for This Patient
This normal AAT level means:
- AAT deficiency is not contributing to her shortness of breath
- She does not have any of the common deficiency genotypes (PIZZ, PISZ, PI*SS) that cause respiratory disease 6
- She is not a candidate for augmentation therapy, which is reserved for patients with AAT <57 mg/dL 2, 3
- Her respiratory symptoms require investigation for other causes
What to Do Next
Pursue standard evaluation for dyspnea, including:
- Complete spirometry (pre- and post-bronchodilator) to assess for obstructive or restrictive patterns 1
- Chest imaging (chest X-ray initially, CT if indicated)
- Assessment for common causes: asthma, COPD (if smoking history), interstitial lung disease, cardiac disease, deconditioning
- Consider bronchodilator trial if airflow obstruction is present
- Evaluate for non-pulmonary causes if pulmonary workup is unrevealing
Important Context About AAT Testing
The guidelines recommend AAT testing in specific populations 6, 1:
- All patients with COPD at diagnosis
- Adults with asthma and persistent airflow obstruction despite treatment
- Unexplained bronchiectasis
- Early-onset emphysema (age ≤45 years)
- Emphysema with basilar predominance
- Family history of AAT deficiency or early lung/liver disease
A critical pitfall to avoid: AAT is an acute-phase reactant that increases during inflammation 7. If this patient had an acute illness or elevated C-reactive protein (CRP) when tested, the AAT level could be falsely elevated. However, at 216 mg/dL, even accounting for acute-phase elevation, she would still have normal baseline levels. Only if AAT were in the borderline range (90-140 mg/dL) would you need to repeat testing when inflammation resolves 2, 7.
When AAT Deficiency Would Be Relevant
For context, AAT deficiency causes respiratory disease when:
- Severe deficiency: PI*ZZ genotype with AAT typically 20-45 mg/dL 1
- Moderate deficiency: PI*SZ genotype with AAT typically 75-120 mg/dL 1
- These patients develop panacinar emphysema, often basilar-predominant, typically presenting in the 4th-5th decade in smokers or 5th-6th decade in never-smokers 6, 8
This patient's normal AAT level excludes these scenarios entirely.